Literature DB >> 18160204

Cholinergic innervation and muscarinic receptors in the human prostate.

Lambertus P W Witte1, Christopher R Chapple, Jean J M C H de la Rosette, Martin C Michel.   

Abstract

OBJECTIVE: In light of recent interest in the use of muscarinic receptor antagonists for the treatment of male lower urinary tract symptoms, understanding how such drugs work not only on the bladder but also on the prostate is important.
METHODS: A literature review was conducted to identify studies on the cholinergic innervation and presence and function of muscarinic acetylcholine receptors in the human prostate.
RESULTS: The available studies demonstrate a dense cholinergic innervation within both stromal and epithelial compartments of the prostate. Concomitantly, the human prostate expresses muscarinic receptors at densities exceeding those of alpha(1)-adrenoceptors. They mainly belong to the M(1) subtype and are found on epithelial cells, but a smaller population of M(2) receptors is found on stromal cells. Both populations have been shown to be functional in signal transduction assays. However, in line with the sparse receptor density on stromal smooth muscle cells, contractile responses of the prostate are only small. Data from prostate cancer cell lines and from botulinum toxin injections into the benign prostate raise the possibility that muscarinic receptors may promote prostatic growth. Animal data suggest that muscarinic receptors may be of primary importance in the genesis of prostatic secretions, but this needs to be confirmed in humans.
CONCLUSIONS: Taken together it appears that direct effects on the prostate need to be considered when using muscarinic receptor antagonists in men. They may primarily involve alterations of glandular secretion and prostatic growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160204     DOI: 10.1016/j.eururo.2007.12.007

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

1.  Autonomic nerve development contributes to prostate cancer progression.

Authors:  John Bauman; Kevin McVary
Journal:  Asian J Androl       Date:  2013-09-30       Impact factor: 3.285

Review 2.  Neuronal Activity in Ontogeny and Oncology.

Authors:  Humsa Venkatesh; Michelle Monje
Journal:  Trends Cancer       Date:  2017-02-13

3.  Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer.

Authors:  Liqiang Guo; Yuqiang Liu; Zhibo Ding; Wendong Sun; Mingzhen Yuan
Journal:  Oncol Lett       Date:  2015-10-27       Impact factor: 2.967

Review 4.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 5.  Muscarinic receptor agonists and antagonists: effects on cancer.

Authors:  Eliot R Spindel
Journal:  Handb Exp Pharmacol       Date:  2012

6.  Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications?

Authors:  Lambertus P W Witte; Christine A Teitsma; Jean J M C H de la Rosette; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-06       Impact factor: 3.000

Review 7.  Established and emerging treatments for diabetes-associated lower urinary tract dysfunction.

Authors:  Betül R Erdogan; Guiming Liu; Ebru Arioglu-Inan; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-12       Impact factor: 3.195

Review 8.  Use of botulinum toxin for voiding dysfunction.

Authors:  David Eldred-Evans; Prokar Dasgupta
Journal:  Transl Androl Urol       Date:  2017-04

9.  Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.

Authors:  João Silva; Rui Pinto; Tiago Carvalho; Francisco Botelho; Pedro Silva; Rui Oliveira; Carlos Silva; Francisco Cruz; Paulo Dinis
Journal:  BMC Urol       Date:  2009-08-15       Impact factor: 2.264

10.  Non-Hormonal treatment of BPH/BOO.

Authors:  Nadir I Osman; Altaf Mangera; Christopher R Chapple
Journal:  Indian J Urol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.